Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics Inc. (NASDAQ: SMMT) announced the successful closing of its rights offering, raising $75 million from the sale of 14,312,976 shares at $5.24 each. The offering incurred approximately $200,000 in expenses, resulting in net proceeds of $74.8 million. Following this issuance, the total shares outstanding is 97,244,567. CEO Mr. Duggan emphasized the offering allowed all stockholders to participate based on their ownership. Unexercised subscription rights expired on May 10, 2021.
Summary not available.
Summit Therapeutics Inc. (NASDAQ: SMMT) announced an impending expiration of its rights offering at 5:00 PM EDT on May 10, 2021. Shareholders must act quickly, as brokerage deadlines may begin today, May 5. The offering entails up to 14,312,977 shares with a total value of up to $75 million. The subscription price will be the lower of $5.24 or the volume-weighted average price over the last ten trading days. Notably, CEO Robert Duggan plans to exercise both his basic and oversubscription rights.
Summit Therapeutics announces a rights offering to raise up to $75 million by issuing 14,312,977 shares of common stock. The offering, effective April 21, 2021, allows existing stockholders, as of April 9, 2021, to purchase shares at $5.24 each or at a lower volume-weighted average price if applicable. Subscription rights must be exercised by May 10, 2021. Non-transferable rights will have no value if not exercised before the expiration date. Further details can be found in the prospectus filed with the SEC.
Summit Therapeutics (NASDAQ: SMMT) announced a rights offering for all stockholders as of April 9, 2021, allowing shares to be purchased at a maximum of $5.24 each. The offering could raise up to $75 million. Additionally, Executive Chairman Robert W. Duggan, holding 69% of shares, is expected to fully participate. The company also issued a $55 million promissory note, with an interest rate projected at 2.4%. Funds will support ongoing clinical trials for ridinilazole and other development efforts.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported its financial results for Q4 and full year 2020, showing a net loss of $52.7 million compared to $29.1 million in 2019. As of March 12, 2021, the company has enrolled 581 patients in its Phase 3 Ri-CoDIFy clinical trials for ridinilazole, aiming to treat C. difficile infection with a target of 1,360 patients. Financial support from BARDA has reached $53.3 million, with a potential total of $72.5 million. The company ended 2020 with cash and equivalents of $66.4 million, sufficient to cover expenses into Q4 2021.
Summit Therapeutics announced the appointment of Dr. Mahkam Zanganeh as Chief Operating Officer, effective immediately. Previously a board member, Dr. Zanganeh brings strategic leadership and extensive operational expertise. Her past experience includes roles at Pharmacyclics, where she played a pivotal role in licensing deals. The company aims to enhance treatment for C. difficile infections through its lead candidate, ridinilazole, currently in Phase 3 trials. The leadership change is expected to strengthen the company’s position in antibiotic innovation.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported its financial results for Q3 and nine months ending September 30, 2020. Patient enrollment in the Phase 3 Ri-CoDIFy trials for ridinilazole reached 448 as of November 15, 2020. However, uncertainties due to COVID-19 have led to a withdrawal of public commentary on trial completion timing. Financial highlights include cash and cash equivalents of $21.3 million, down from $63.8 million in December 2019, and a net loss of $39.3 million for the nine months ended September 30, 2020, up from $20.0 million in the same period the previous year.
Summit Therapeutics has successfully completed a $50 million private placement, issuing shares of common stock to its CEO, Robert W. Duggan, and two additional investors. A total of 14,071,856 shares were sold to Duggan and 898,204 shares to other investors at a price of $3.34 per share, matching the previous Nasdaq closing price. The proceeds are expected to support the Ri-CoDIFy Phase 3 clinical trial for ridinilazole and other early-stage projects, extending the company's cash runway into Q4 2021.
Summit Therapeutics announced a fundraising agreement worth approximately $50 million with CEO Robert W. Duggan. This private placement involves issuing up to 14,970,060 shares at a price of $3.34 per share, with a minimum of 9,730,539 shares to be sold. The funds will extend the company's cash runway into the third quarter of 2021, supporting the ongoing Ri-CoDIFy Phase 3 clinical trial for ridinilazole and preparatory activities for its potential commercial launch.